Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
674 stopped studies mapped to Digestive System Adenocarcinoma and descendants · 93% state a reason
Over the 674 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06882746 | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon,… | Phase 1 | terminated | Mar 19, 2025 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT05908786 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in… | Phase 1 / Phase 2 | terminated | Jun 18, 2023 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT06968195 | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or… | Phase 1 | suspended | May 13, 2025 | Roswell Park Cancer Institute | awaiting agreement with Sponsor | Other (stated, no rule matched) |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Phase 2 | suspended | Oct 1, 2019 | Thomas Jefferson University | Protocol is with FDA review, waiting for funding to be released | Funding |
| NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular…(CLeAR) | Phase 1 | withdrawn | Jan 26, 2026 | Virginia Commonwealth University | The study was withdrawn because the pharmaceutical company decided not to pursue this combination… | Sponsor / business decision |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for…(FORTITUDE-102) | Phase 3 | terminated | Nov 8, 2021 | Amgen | Study was terminated by sponsor | Other (stated, no rule matched) |
| NCT05685602 | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic… | Phase 1 | suspended | Jan 17, 2023 | National Cancer Institute (NCI) | Drug Supply Issues | Drug supply |
| NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in… | Phase 3 | terminated | Jan 29, 2020 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT06929338 | xDRIVE in Metastatic Colorectal Cancer | — | withdrawn | Apr 16, 2025 | First Ascent Biomedical Inc. | Unable to finalize study agreements | Other (stated, no rule matched) |
| NCT04601428 | Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC) | Early Phase 1 | terminated | Oct 23, 2020 | Koo Foundation Sun Yat-Sen Cancer Center | The decision has been made to terminate the study due to logistical reasons and not due to any… | Safety / toxicity |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | suspended | Oct 1, 2024 | Children's Oncology Group | Unacceptable Toxicity | Safety / toxicity |
| NCT06250036 | Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer(ZODIAC) | Phase 2 | suspended | Feb 8, 2024 | Royal Marsden NHS Foundation Trust | Gilead's ongoing evaluation of the wider Zimberelimab and Domvanalimab programme, following the… | Safety / toxicity |
| NCT05435014 | T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Jun 28, 2022 | T-ACE Medical Co., Ltd | T-ACE Medical Co., Ltd. hereby submits this formal notification to the U.S. Food and Drug… | Other (stated, no rule matched) |
| NCT05791448 | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver… | Phase 1 | suspended | Mar 30, 2023 | University of Southern California | Pending protocol amendment | Other (stated, no rule matched) |
| NCT05286827 | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | Phase 2 | terminated | Mar 18, 2022 | National Cancer Institute (NCI) | The study was terminated due to low accrual and insufficient efficacy seen in first few… | Efficacy / futility |
| NCT05737615 | PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal,… | Phase 1 | withdrawn | Feb 21, 2023 | Memorial Sloan Kettering Cancer Center | Study tracer is currently unavailable | Other (stated, no rule matched) |
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed… | Phase 2 | terminated | Jan 20, 2022 | Academic and Community Cancer Research United | Sponsor has withdrawn support for the study. | Other (stated, no rule matched) |
| NCT03695250 | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver… | Phase 1 / Phase 2 | terminated | Oct 4, 2018 | Edward Kim | Funding source decision to terminate study. | Funding |
| NCT06528093 | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With… | Phase 1 | terminated | Jul 30, 2024 | Boehringer Ingelheim | not stated | Not stated |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT05705791 | Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial…(HOLMBRAVE) | N/A | terminated | Jan 31, 2023 | Gustave Roussy, Cancer Campus, Grand Paris | Toxicities | Safety / toxicity |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… | Phase 1 | terminated | Sep 5, 2024 | BeOne Medicines | The Sponsor has made the decision to terminate this study due to the lack of promising efficacy,… | Efficacy / futility |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Phase 1 | terminated | Jun 20, 2024 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT04809766 | Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic… | Phase 1 | terminated | Mar 22, 2021 | Fred Hutchinson Cancer Center | Study terminated due to end of funding. | Funding |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating… | Phase 2 | terminated | Jun 6, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation(NIVOLEP) | Phase 2 | terminated | Aug 15, 2018 | Assistance Publique - Hôpitaux de Paris | Because patient recruitment was affected by the COVID-19 pandemic, the study sponsor and funding… | COVID-19 / pandemic |
| NCT04975516 | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for… | Phase 2 | terminated | Jul 23, 2021 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | terminated | Aug 24, 2022 | Day One Biopharmaceuticals, Inc. | Development discontinued. | Other (stated, no rule matched) |
| NCT05537402 | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC(LOST-B) | Phase 2 | terminated | Sep 13, 2022 | University of Texas Southwestern Medical Center | The decision was made to close the study to enrollment due to poor overall accrual and the… | Enrollment / accrual |
| NCT02626312 | Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma,… | Phase 1 | terminated | Dec 10, 2015 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT06902246 | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | Phase 2 | withdrawn | Mar 30, 2025 | University of Miami | Investigator decision | Investigator |
| NCT05419479 | Switch Maintenance in Pancreatic | Phase 1 / Phase 2 | suspended | Jun 15, 2022 | James Cleary, MD, PhD | Efficacy concerns. | Efficacy / futility |
| NCT05275075 | Identify microRNAs in Cachexia in Pancreatic Carcinoma(SCC-miRPanCa) | — | terminated | Mar 11, 2022 | University of Oklahoma | Translational scientist left university | Other (stated, no rule matched) |
| NCT06405061 | Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and… | Phase 2 | suspended | May 8, 2024 | Tianjin Medical University Cancer Institute and Hospital | Mid-term data analysis for the project has been completed; enrollment is now suspended. | Enrollment / accrual |
| NCT04975217 | Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | Early Phase 1 | suspended | Jul 23, 2021 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT02928627 | Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in… | — | terminated | Oct 10, 2016 | University of Aberdeen | The project did not progress as there were no findings available for the lab analysis of microRNA… | Other (stated, no rule matched) |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | Phase 1 / Phase 2 | suspended | Jan 20, 2022 | University of Chicago | enrollment goal met pending determination of evaluable subjects | Enrollment / accrual |
| NCT06653023 | Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer(Wondercel-UWD3) | Early Phase 1 | suspended | Oct 22, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT05027425 | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed… | Phase 2 | terminated | Aug 30, 2021 | University of Cincinnati | The study is closing due to low enrollment and feasibility of the study. | Enrollment / accrual |
| NCT02908048 | Extracellular RNA Markers of Liver Disease and Cancer | — | terminated | Sep 20, 2016 | Mayo Clinic | Ran out of funds | Funding |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for… | Phase 2 | terminated | Jul 26, 2019 | National Cancer Institute (NCI) | Scientific reprioritization. Closed per principal investigator discretion to prioritize enrollment… | Investigator |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2023 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT02072616 | Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.(CTC-Pancreas) | N/A | terminated | Feb 26, 2014 | University Hospital, Rouen | Analysis not possible at the stage | Other (stated, no rule matched) |
| NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or… | Phase 2 | withdrawn | Jul 22, 2020 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT05718882 | Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC | N/A | terminated | Feb 8, 2023 | RenJi Hospital | The study was terminated because the originally planned VIC-1911 dose-escalation scheme (100 mg,… | Safety / toxicity |
| NCT05103904 | Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | Phase 2 | terminated | Nov 2, 2021 | Emory University | Slow Accrual | Enrollment / accrual |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers… | Phase 1 / Phase 2 | terminated | May 13, 2020 | University of Southern California | Study drug no longer available | Other (stated, no rule matched) |
| NCT07040059 | A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and… | Phase 1 / Phase 2 | terminated | Jun 26, 2025 | Aurigene Discovery Technologies Limited | Patient recruitment problems. | Enrollment / accrual |
| NCT05567835 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in…(TOGAR) | Phase 2 | terminated | Oct 5, 2022 | Baylor College of Medicine | Since activation, 3 subjects were enrolled but were ineligible for randomization to a treatment arm… | Enrollment / accrual |
| NCT03727633 | Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial…(LIDA-BII) | Phase 2 | terminated | Nov 1, 2018 | University Hospital, Montpellier | Enrollement rythm low, funding body decision. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials